US adopts cadaver‑fat injections to restore volume lost from GLP‑1 drugs

AlloClae, a cosmetic injectable made from donated human cadaver fat, has been marketed in the United States by Tiger Aesthetics. The product is administered in under an hour, requires no general anesthesia and promises rapid recovery. Since its launch in May 2025, more than 2,000 patients have received the treatment, according to the company.

The rise of alloClae is linked to the growing use of GLP‑1 weight‑loss drugs such as Ozempic and Wegovy, which cause rapid fat loss and leave patients with hollowed‑out facial, breast and gluteal areas. Plastic surgeon Luis Macias notes that many of his GLP‑1 patients seek “to restore volume in the breasts, glutes and face.”

Patients such as Sandra, a Los Angeles‑based media lawyer, have embraced the option, saying, “You reach a certain age and decide: ‘I’m going to do something for myself now.’” The procedure’s cost per 12.5 cc syringe is about US$2,250, with full treatment courses reaching tens of thousands of dollars.

The technique has sparked ethical debate. Bioethicist Arthur Caplan warned that commercializing donated tissue “betrays altruism,” while regulators in some states have yet to provide clear oversight. Critics label the filler “zombie fat,” while supporters call it a new‑generation aesthetic solution.